239 related articles for article (PubMed ID: 17085197)
1. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins.
Moltedo B; Faunes F; Haussmann D; De Ioannes P; De Ioannes AE; Puente J; Becker MI
J Urol; 2006 Dec; 176(6 Pt 1):2690-5. PubMed ID: 17085197
[TBL] [Abstract][Full Text] [Related]
2. Immunodominant role of CCHA subunit of Concholepas hemocyanin is associated with unique biochemical properties.
Becker MI; Fuentes A; Del Campo M; Manubens A; Nova E; Oliva H; Faunes F; Valenzuela MA; Campos-Vallette M; Aliaga A; Ferreira J; De Ioannes AE; De Ioannes P; Moltedo B
Int Immunopharmacol; 2009 Mar; 9(3):330-9. PubMed ID: 19159699
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
Lamm DL; DeHaven JI; Riggs DR; Ebert RF
J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
6. Enhanced structural stability of Concholepas hemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects.
Arancibia S; Del Campo M; Nova E; Salazar F; Becker MI
Eur J Immunol; 2012 Mar; 42(3):688-99. PubMed ID: 22144228
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin.
Sargent ER; Williams RD
Urol Clin North Am; 1992 Aug; 19(3):581-9. PubMed ID: 1378983
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
10. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.
Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R
Urol Res; 1993 Jan; 21(1):33-7. PubMed ID: 8456536
[TBL] [Abstract][Full Text] [Related]
11. Keyhole-limpet haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma.
Walsh WG; Tomashefsky P; Olsson CA; deVere White R
Urol Res; 1983; 11(6):263-5. PubMed ID: 6659223
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of interleukin-12 against murine bladder cancer.
Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.
Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL
J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535
[TBL] [Abstract][Full Text] [Related]
15. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer.
Mora Román JJ; Del Campo M; Villar J; Paolini F; Curzio G; Venuti A; Jara L; Ferreira J; Murgas P; Lladser A; Manubens A; Becker MI
J Immunol Res; 2019; 2019():7076942. PubMed ID: 30847353
[TBL] [Abstract][Full Text] [Related]
17. [Cancer immunotherapy by murine bladder cancer cells transfected with mouse interferon-gamma gene].
Hashimura T; Hiura M; Yoshida O; Teramura Y; Kuribayashi K; Watanabe Y
Hinyokika Kiyo; 1993 Dec; 39(12):1205-8. PubMed ID: 8285171
[TBL] [Abstract][Full Text] [Related]
18. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
19. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer.
Wishahi MM; Ismail IM; Ruebben H; Otto T
J Urol; 1995 Mar; 153(3 Pt 2):926-8. PubMed ID: 7853576
[TBL] [Abstract][Full Text] [Related]
20. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
